Description The new anti-cancer drug ibrutinib (Imbruvica), developed by the J & J pharmaceutical company is significantly more effective than standard chemotherapy for leukemia. This is evidenced by the results of clinical studies published in The Daily Mail. During the trial, some patients with chronic lymphocytic leukemia received ibrutinib, and some patients received chemotherapy. It...